Nasdaq
$4.96▲ 0.20%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $66.8MShares out 13.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 10.2After-hours26.10.03 06:004Ownership#●●●
Cingulate Inc.
Cingulate Inc. insider Raul R. Silva filed a Form 4 statement on October 2, 2026, reporting changes in beneficial ownership of securities as of September 30, 2026. This filing serves as an official record of the insider's equity transaction.…more
$4.96+0.20%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 05:308-KKey event
Cingulate Inc.
Cingulate Inc. has amended the employment agreement of its Chief Medical Officer, Matthew N. Brams, extending his full-time trial period from September 30, 2026, to December 31, 2026. During this period, his annual base salary remains $400,000, and the decision to maintain his full-time role thereafter rests solely with the CEO.…more
$4.96+0.20%vs prev closeView filingShare - 8.13Pre-market26.08.13 21:4510-QEarnings
Cingulate Inc.
Cingulate Inc. filed its quarterly report (Form 10-Q) for the period ended June 30, 2026, reporting 14,541,826 shares of common stock issued and outstanding. The filing includes management certifications regarding the company's financial condition and operational results, with no specific earnings figures or material corporate changes disclosed.…more
$4.96+0.20%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.17Pre-market26.09.17 21:05#●●●#●●●
Cingulate Executives to Present Commercialization Strategy at Indegene Summit…more
Cingulate leadership will participate in an industry summit to discuss commercialization strategies for its lead ADHD candidate, CTx-1301. This event focuses on strategic planning and does not represent new regulatory approvals or financial results.…more
$4.96+0.20%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.13Pre-market26.08.13 21:30
●●●●●●●● ●●●●● ●●●●●●
Cingulate is advancing manufacturing updates for its ADHD drug CTx-1301 to support an FDA resubmission while maintaining a cash runway through mid-2027. The company is also actively preparing for commercialization through new distribution partnerships and operational scaling.…more
$4.96+0.20%vs prev close - 8.11Pre-market26.08.11 21:30
●●●●●●●● ●●●●● ●●●●●●
싱귤레이트가 자사의 ADHD 치료제 후보물질 CTx-1301의 차별화된 약동학적 프로파일을 입증한 연구 결과를 동료 심사 학술지에 게재했다. 이번 데이터는 기존 치료제 대비 우수한 약물 전달 효율과 안전성을 확인하며 향후 임상 및 상용화 기대감을 높였다.…more
$4.96+0.20%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report